08:00 , Dec 6, 2010 |  BC Week In Review  |  Clinical News

Cel-Sci preclinical data

In a mouse model of collagen-induced arthritis, a single dose of CEL-2000 formulated with DepoVax delivery technology from ImmunoVaccine Inc. (TSX-V:IMV, Halifax, Nova Scotia) slowed the progression of RA and significantly reduced Arthritic Index...
07:00 , Oct 26, 2009 |  BC Week In Review  |  Clinical News

Cel-Sci preclinical data

In mice, CEL-2000 significantly reduced joint inflammation as measured by visual inspection and foot pad thickness. The vaccine formulated using Cel-Sci's Ligand Epitope Antigen Presentation System ( L.E.A.P.S.) T cell modulation platform technology also showed...
07:00 , Sep 15, 2008 |  BC Week In Review  |  Clinical News

Cel-Sci preclinical data

In a mouse model of RA, CEL-2000 was as good as Enbrel etanercept in slowing disease progression. Amgen Inc. (NASDAQ:AMGN, Thousand Oaks, Calif.) co-markets Enbrel in the U.S. and Canada with Wyeth...